Is that the building window maker in South America? I remember Van and I discussed TGLS during the Lockdown. It’s been on a tear, what a great move! Thanks for the idea!
--Applied UV in strategic financial collaboration with Canon Financial Services » 07:15 AUVI --Lithium Ionic reports assay results from hole at Bandeira property 07:10 LTHCF --Foot Locker downgraded to Sell from Neutral at UBS » 06:17 FL --Invitation Homes initiated with an Overweight at Wells Fargo 17:24 INVH Wells Fargo initiated coverage of Invitation Homes with an Overweight rating and $33.50 price target. Invitation is the largest single-family rental platform "with room to grow," the analyst tells investors in a research note. --CymaBay management to meet with Cantor Fitzgerald 17:25 CBAY Biotech Analyst Kluska holds a dinner meeting with President & CEO Shah, CSO McWherter and CCO Stuart in New York on March 28 at 6 pm hosted by Cantor Fitzgerald.
Arcturus Therapeutics reports Q4 EPS $4.33, consensus 98c 16:03 ARCT Reports Q4 revenue $160.3M, consensus $72.68M. "Arcturus has continued to make remarkable operational and pipeline progress. This was recently exemplified by the completion of the initial objectives with our partnered COVID-19 and Flu vaccine programs with CSL," said Joseph Payne, President and CEO of Arcturus Therapeutics. "We are also pleased to report the completion of full enrollment ahead of schedule in the Phase 3 study being conducted by Meiji Pharma to evaluate ARCT-154 as a booster vaccine for COVID-19."
Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 15:38 HRMY Mizuho notes Harmony Biosciences shares were down 26% intra-day following the release this morning of a short report by Scorpion Capital, an activist short selling-focused firm known for targeting biotech companies. based on the firm's cursory view of the 366-page long report, Mizuho said the report's "language, accounts, and evidence are potentially misleading and inflated, perhaps even sensational in nature." The firm's Buy thesis on Harmony has been based on a view that company fundamentals are overall strong, as Wakix is an effective and safe, unscheduled drug, and is not significantly restricted by payors, prospects on further market penetration/expansion in narcolepsy remain healthy, and Wakix faces little current competitive threat, said Mizuho, which keeps a Buy rating and $60 price target on Ha BUY IDEA #2 HRMY->$30.90
Transocean wins contract award, extension totaling $113M Mar. 29, 2023 7:17 AM ETTransocean Ltd. (RIG) Transocean (NYSE:RIG)+1.3%pre-market Wednesday after announcing contract fixtures for two of its harsh environment semisubmersibles, adding $113M to its firm contract backlog. In Australia, theTransocean Endurancewas awarded a multi-well plug and abandonment contract
Honeywell expects air-taxi growth to boom in 2030 after limited use Why did Snap stock fall almost 6% Tuesday? Heavy activity after executive change